TRIPS and Special & Differential Treatment – Revisiting the Case for Derogations in Applying Patent Protection for Pharmaceuticals in Developing Count

In this paper we apply an implicit threshold approach, malleable to the principle of graduation, toidentify countries that should benefit from derogations from WTO TRIPS commitments forpharmaceutical patents under the tenets of Special and Differential Treatment. This is based on theidentification of four broad constraints loosely classified as; economic constraints; access topharmaceuticals; capacity constraints; and incidence of health outcomes. We identify these by meansof analytical criteria and create a composite index that ranks countries according to the observedconstraints which delimit the capabilities and desirability of implementing TRIPs disciplines. Wediscuss the use of negotiated weights and thresholds in determining participation and graduation intogeneral provisions of the agreement. It follows that countries below the chosen threshold should beexempt from these hence receiving Special and Differential Treatment.

[1]  Javier Lopez-Gonzalez,et al.  Towards a New Age in Special and Differential Treatment , 2011 .

[2]  Charles T. Collins-Chase.  The Case against TRIPS-Plus Protection in Developing Countries Facing Aids Epidemics , 2008 .

[3]  T. Cottier.  From Progressive Liberalization to Progressive Regulation in WTO Law , 2006 .

[4]  M. Day.  Half a million children a year die of AIDS through lack of drugs , 2006, BMJ : British Medical Journal.

[5]  J. Lanjouw.  A Patent Policy Proposal for Global Diseases , 2006, Innovations: Technology, Governance, Globalization.

[6]  V. Deardoiff.  Should Patent Protection Be Extended to All Developing Countries ? , 2006 .

[7]  A. Attaran.  How do patents and economic policies affect access to essential medicines in developing countries? , 2004, Health affairs.

[8]  L. Winters,et al.  Special and Differential Treatment of Developing Countries in the WTO: Moving Forward after Cancun , 2004 .

[9]  P. Low,et al.  Special and Differential Treatment in the WTO: Why, When and How? , 2004 .

[10]  C. Arndt,et al.  African Development and Poverty Reduction: The Macro-Micro Linkage , 2004 .

[11]  Sandra Freire.  Impact of HIV/AIDS on Saving Behaviour in South Africa , 2004 .

[12]  Sanjaya Lall,et al.  Indicators of the Relative Importance of IPRs in Developing Countries , 2003 .

[13]  H. Grabowski.  Patents, Innovation and Access to New Pharmaceuticals , 2002 .

[14]  T. Lybbert.  On assessing the cost of TRIPS implementation , 2002, World Trade Review.

[15]  Els Torreele,et al.  Drug development for neglected diseases: a deficient market and a public-health policy failure , 2002, The Lancet.

[16]  Alan Sykes,et al.  Trips, Pharmaceuticals, Developing Countries, and the Doha 'Solution' , 2002, Chicago journal of international law.

[17]  C. Stevens.  The future of Special and Differential Treatment (SDT) for developing countries in the WTO , 2002 .

[18]  E. Hoen.  TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. , 2002 .

[19]  C. Arndt,et al.  The HIV/AIDS pandemic in South Africa: sectoral impacts and unemployment , 2001 .

[20]  S. Lowry.  Intellectual Property Rights in the Global Economy , 2001 .

[21]  Intellectual Property : Balancing Incentives with Competitive Access 5 , 2001 .

[22]  K. Anderson.  Agriculture's 'Multifunctionality' and the WTO , 2000 .

[23]  Jayashree Watal,et al.  Pharmaceutical Patents, Prices and Welfare Losses: Policy Options for India Under the WTO TRIPS Agreement , 2000 .

[24]  K. Maskus.  Competition Policy and Intellectual Property Rights in Developing Countries : Interests in Unilateral Initiatives and a WTO Agreement , 2000 .

[25]  Constantine Michalopoulos.  The role of special differential treatment for developing countries in GATT and the World Trade Organization , 1999 .

[26]  Yongmin Chen,et al.  Vertical Price Control and Parallel Imports: Theory and Evidence , 1999 .

[27]  T. Cottier.  The protection of genetic resources and traditional knowledge: towards more specific rights and obligations in world trade law , 1998 .

[28]  W. S. Vicente.  A Questionable Victory for Coerced Argentine Pharmaceutical Patent Legislation , 1998 .

[29]  J. Nogués.  SOCIAL COSTS AND BENEFITS OF INTRODUCING PATENT PROTECTION FOR PHARMACEUTICAL DRUGS IN DEVELOPING COUNTRIES , 1993 .

[30]  Alan V. Deardorff.  Welfare Effects of Global Patent Protection , 1992 .